Global Cell And Gene Therapy Cdmo Market Size & Outlook
Global cell and gene therapy cdmo market, 2018-2030 (US$M)
Related Markets
Global cell and gene therapy cdmo market highlights
- The global cell and gene therapy cdmo market generated a revenue of USD 4,986.2 million in 2023 and is expected to reach USD 27,449.9 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 27.6% by 2030.
- In terms of segment, pre-clinical accounted for a revenue of USD 3,300.7 million in 2023.
- Pre-clinical is the most lucrative by phase segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2023.
- Country-wise, Kuwait is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 4,986.2 million |
| Market revenue in 2030 | USD 27,449.9 million |
| Growth rate | 27.6% (CAGR from 2023 to 2030) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
Other key industry trends
- In terms of revenue, the North America accounted for 40.8% of the global cell and gene therapy cdmo market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Kuwait is the fastest growing regional market and is projected to reach USD 24.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global cell and gene therapy cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.2% in 2023. Horizon Databook has segmented the Global cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Cell And Gene Therapy CDMO by Phase Outlook (Revenue, USD Million, 2018-2030)
- Pre-clinical
- Clinical
- Global Cell And Gene Therapy CDMO by Product Type Outlook (Revenue, USD Million, 2018-2030)
- Gene Therapy
- Ex-vivo
- In-vivo
- Gene-Modified Cell Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- Cell Therapy
- Gene Therapy
- Global Cell And Gene Therapy CDMO by Indication Outlook (Revenue, USD Million, 2018-2030)
- Oncology
- Infectious Diseases
- Neurological disorders
- Rare Diseases
- Others
Reasons to subscribe to Global cell and gene therapy cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global cell and gene therapy cdmo market databook
-
Our clientele includes a mix of cell and gene therapy cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global cell and gene therapy cdmo market , including forecasts for subscribers. This global databook contains high-level insights into Global cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global cell and gene therapy cdmo market size, by regions, 2018-2030 (US$M)
Top 10 countries: Cell and gene therapy cdmo market size, 2023 (US$M)
Global cell and gene therapy cdmo market share, by by phase, 2023 & 2030 (%, US$M)
Cell and gene therapy cdmo market: Opportunity assessment by country
Global cell and gene therapy cdmo market, by region, 2023 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
